Artificial intelligence (AI) already is making a difference in healthcare by helping medical professionals interpret tests, clarify diagnoses and identify the most effective treatment approaches to a range of diseases. As Cedars-Sinai explores new uses of AI, it is balancing the rapid development of this emerging technology with responsible and ethical implementation. “AI systems have the power to transform healthcare,” said Mike Thompson, vice president of Enterprise Data Intelligence at Cedars-Sinai. “If implemented properly and responsibly, AI can be deployed to enhance patient experience, improve population health, reduce costs and improve the work life of healthcare providers.” Thompson sat down…
Author: Abhay Panchal
A next-generation, multitarget stool DNA test, known as the next-generation Cologuard, has demonstrated a 94% sensitivity and 91% specificity in detecting colorectal cancer, surpassing the performance of fecal immunochemical testing (FIT). Thomas F. Imperiale, MD, from Indiana University Medical Center, highlighted that this version of Cologuard differs from FIT due to its unique markers, which are all methylated DNA markers. In the BLUE-C study, which involved 26,758 participants, the next-generation Cologuard showed a higher likelihood of detecting cancer (94% vs. 67%) and precancerous lesions (43% vs. 23%) compared to FIT. Imperiale emphasized the significance of the improved specificity, which is…
Motus GI Holdings, Inc., a medical technology company focused on enhancing endoscopic outcomes, has announced that it has secured clearance from the U.S. Food and Drug Administration (FDA) for its new Pure-Vu EVS Gastro and Gen 4 Colon system. This clearance paves the way for the company to tap into the upper gastrointestinal (GI) market, addressing the needs of patients with upper GI bleeds, a condition with high mortality rates. The new Pure-Vu systems offer significant improvements over previous models, aiming to provide better visualization in both the upper and lower GI tracts. These advancements include a more powerful suction…
Microsoft and Google have recently introduced new features for their healthcare cloud products, aiming to consolidate data from diverse sources such as EHRs, labs, revenue cycles, and more. This integration will enable healthcare organizations to derive insights from various datasets or establish standardized processes. Key Points:
American patients are divided regarding their comfort with the application of artificial intelligence (AI) in their healthcare experiences. A survey conducted by Propeller Insights on behalf of Carta Healthcare revealed the following:
The gastroenterology industry is witnessing rapid advancements with the integration of artificial intelligence and innovative technologies, offering specialists novel methods to care for and treat patients. Here are five groundbreaking GI-industry devices:
An app-based digital therapeutic has shown significant efficacy in reducing symptoms and enhancing the quality of life, work productivity, and health literacy among patients with irritable bowel syndrome (IBS). These findings are from the ColoFuture Study, presented at the UEG Week 2023. Key Findings:
In this month’s column, I highlight three topics that are highly relevant to endoscopy clinical practice: colon polyp sizing, Helicobacter pylori’s relationship with gastric cancer and large nonpedunculated polyps. Although pathologists report the size of colon polyps resected during colonoscopy, the accuracy of such size reporting is questionable. In this study, investigators showed that due to factors such as piecemeal resection, only 60% of polyps sent to pathology can be measured, and of those that are measured, shrinkage of polyp size occurs in almost 25% of the specimens. The majority of the results showing a reduction in gastric incidents after…
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has unveiled the significant findings of its ColoFuture Study. The study was initially set for presentation at the 4th International Conference on Gastroenterology in Paris but was rescheduled. Despite the change, Mainz Biomed decided to release the results as per the original conference timeline. Key Findings:
Alimentiv Inc., a prominent Contract Research Organization specializing in GI-related therapeutics, has announced the inclusion of new scientific advisors to its scientific advisory board. These advisors are globally acknowledged experts in designing and conducting clinical research in Inflammatory Bowel Disease (IBD). Their significant contributions have been pivotal in advancing the development of innovative IBD therapies and enhancing patient outcomes. Highlighted Advisors: Dr./Prof. Remo Panaccione: A Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He is also the Dean of MD Admissions and Director of the IBD Fellowship Program. Dr.…